Hepatitis C Newsletter
www.HepCChallenge.org
July 2011
Clinical
Trials, Cohort Studies, Pilot Studies
Outcomes
of treatment for hepatitis C virus infection by primary care providers. Arora S, Thornton K, Murata G, et al. N
Engl J Med. 2011 Jun 9;364(23):2199-207.
Epub 2011 Jun 1.
http://www.ncbi.nlm.nih.gov/pubmed/21631316
Genetic
variation in interleukin 28B with respect to vertical transmission of hepatitis
C virus and spontaneous clearance in HCV-infected children. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, et al. Hepatology. 2011
Jun;53(6):1830-8. doi: 10.1002/hep.24298.
http://www.ncbi.nlm.nih.gov/pubmed/21413051
Telaprevir for
retreatment of HCV infection. Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28.
http://www.ncbi.nlm.nih.gov/pubmed/21696308
A Poxvirus Vaccine Is Safe,
Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic
Hepatitis C. Habersetzer F, Honnet
G, Bain C, et al. Gastroenterology. 2011 Jun 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21699798
Rate of Progression of Hepatic
Fibrosis in Patients with Chronic Hepatitis C: Results from the HALT-C Trial. Hoefs JC, Shiffman ML, Goodman
ZD, et al. Gastroenterology. 2011 Jun 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21699796
Optimal
follow-up time to determine the sustained virological
response in patients with chronic hepatitis C receiving Peg-IFN and ribavirin. Namikawa M, Kakizaki S, Yata Y, et al. J Gastroenterol Hepatol. 2011 Jun 7. doi:
10.1111/j.1440-1746.2011.06802.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21649727
Prognostic
factors in patients with hepatitis C virus infection and systemic vasculitis. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Arthritis
Rheum. 2011 Jun;63(6):1748-57. doi: 10.1002/art.30319.
http://www.ncbi.nlm.nih.gov/pubmed/21400476
A prospective study of T- and
B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients
with chronic HCV infection during pegylated
interferon-alpha2a plus ribavirin treatment.
Soldevila B,
Alonso N, Martínez-Arconada MJ, et al. J Viral Hepat. 2011 Jun;18(6):384-92. doi:
10.1111/j.1365-2893.2010.01317.x.
http://www.ncbi.nlm.nih.gov/pubmed/20487258
All-Cause, Liver-Related, and
Non-Liver-Related Mortality Among HCV-Infected
Individuals in the General US Population. El-Kamary SS, Jhaveri R, Shardell MD. Clin Infect Dis. 2011 Jul;53(2):150-7. Epub 2011 Jun 10.
http://www.ncbi.nlm.nih.gov/pubmed/21665867
Effect of
combined siRNA of HCV E2 gene and HCV receptors
against HCV.
Jahan S, Khaliq S, Samreen B, et al. Virol J. 2011
Jun 10;8(1):295. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21663667
Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral
Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large
Multicenter Cohort Study. ReViS-TC
Study Group. Transplantation. 2011 Jun 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21659948
Randomised clinical trial:
anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Bergmann
JF, de Bruijne J, Hotho DM,
et al. Aliment Pharmacol Ther. 2011 Jun 26. doi:
10.1111/j.1365-2036.2011.04745.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21707679
Genome-wide association study
identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin
therapy for chronic hepatitis C.
Tanaka
Y, Kurosaki M, Nishida N, et al. Hum Mol Genet. 2011 Jun 23.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21659334
Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin
in Patients with Genotype 3 Chronic Hepatitis C. Tohra SK, Taneja S, Ghosh S, et al. Dig Dis Sci. 2011 Jun 25. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21706207
Retreatment
of patients with chronic hepatitis C relapsers to a
previous antiviral treatment. Floreani A, Cazzagon N, Furlan P, et al. Eur J Gastroenterol Hepatol. 2011 Jun 4. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21654322
Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients
with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled
Trials.
Singal AK, Jampana SC, Anand BS. Dig Dis Sci. 2011 Jun 4. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21643737
Retreatment of Hepatitis C with
Consensus Interferon and Ribavirin After
Nonresponse or Relapse to Pegylated
Interferon and Ribavirin: A National VA Clinical
Practice Study.
Yee HS,
Currie SL, Tortorice K, et al. Dig Dis Sci. 2011 Jun 2. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21633833
Role of Interleukin 28B rs12979860 C/T
Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship
with Gender and Viral Genotype. Falleti E,
Bitetto D, Fabris C, et al.
J Clin Immunol. 2011 Jun 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21647799
Serodiagnosis of Helicobacter hepaticus
infection in patients with liver and gastrointestinal diseases: western blot
analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen. Murakami K, Takahashi
R, Ono M, et al. J Gastroenterol. 2011
Jun 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21656014
Basic
and Applied Science, Pre-Clinical Studies
Common
genetic polymorphism of ITPA gene affects ribavirin-induced
anemia and effect of peg-interferon plus ribavirin
therapy. Azakami T, Hayes CN, Sezaki
H, et al. J Med Virol. 2011 Jun;83(6):1048-57.
doi: 10.1002/jmv.22069.
http://www.ncbi.nlm.nih.gov/pubmed/21503919
Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8
expression on peripheral CD4+ and CD8+ T-cells. Arends JE, Hoepelman
AI, Nanlohy NM, et al. Apoptosis. 2011 Jun 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21667042
Preexisting drug-resistance mutations reveal
unique barriers to resistance for distinct antivirals.
Robinson M, Tian Y,
Delaney WE 4th, Greenstein AE. Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10290-5. Epub 2011 Jun 6.
http://www.ncbi.nlm.nih.gov/pubmed/21646519
Effects
of hepatitis C virus on suppressor of cytokine signaling mRNA levels:
comparison between different genotypes and core protein sequence analysis. Pascarella S, Clément
S, Guilloux K, Conzelmann
S, Penin F, Negro F. J Med Virol.
2011 Jun;83(6):1005-15. doi: 10.1002/jmv.22072.
http://www.ncbi.nlm.nih.gov/pubmed/21503913
A genetically humanized mouse model for hepatitis C
virus infection. Dorner M, Horwitz
JA, Robbins JB, et al. Nature. 2011 Jun 8;474(7350):208-11.
doi: 10.1038/nature10168.
http://www.ncbi.nlm.nih.gov/pubmed/21654804
Sequence heterogeneity of NS5A and core proteins of
hepatitis C virus and virological responses to pegylated-interferon/ribavirin
combination therapy. El-Shamy
A, Shoji I, Saito T, et al. Microbiol Immunol.
2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.
http://www.ncbi.nlm.nih.gov/pubmed/21371092
Neurotoxic effects of the HCV core protein
are mediated by sustained activation of ERK via TLR2 signaling. Paulino AD, Ubhi K, Rockenstein E, et al. J Neurovirol.
2011 Jun 10. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21660601
HIV/HCV/HBV
Coinfection
Molecular characterization of
hepatitis C virus genotype 4 sequences in HIV-coinfected
patients from Argentina. Bolcic F,
Jones LR, Laufer N, Quarleri
J. J Med Virol. 2011 Jun;83(6):935-40.
doi: 10.1002/jmv.22068.
http://www.ncbi.nlm.nih.gov/pubmed/21503903
Liver
Toxicity of Antiretroviral Combinations Including Fosamprenavir
Plus Ritonavir 1400/100 mg
Once Daily in HIV/Hepatitis C Virus-Coinfected
Patients. Merchante N, López-Cortés
LF, Delgado-Fernández M, et al. AIDS Patient Care
STDS. 2011 Jun 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21688986
Do rates of unprotected anal
intercourse among HIV-positive MSM present a risk for hepatitis C transmission?
Stall R, Wei C, Raymond HF, McFarland W. Sex Transm
Infect. 2011 Jun 8. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21653934
Presence of occult HBV, but near
absence of active HBV and HCV infections in people infected with HIV in rural
South Africa. Barth RE, Huijgen Q, Tempelman HA, et al. J Med Virol. 2011
Jun;83(6):929-34. doi: 10.1002/jmv.22026.
http://www.ncbi.nlm.nih.gov/pubmed/21503902
Ethnic
differences in viral dominance patterns in patients with hepatitis B virus and
hepatitis C virus dual infection. Nguyen LH, Ko
S, Wong SS, et al. Hepatology. 2011 Jun;53(6):1839-45. doi:
10.1002/hep.24308.
http://www.ncbi.nlm.nih.gov/pubmed/21425314
The Relation
of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in
HIV-Infected and HIV-Uninfected Women. Kuniholm MH, Gao X, Xue X, et al. J Infect
Dis. 2011 Jun;203(12):1807-14.
http://www.ncbi.nlm.nih.gov/pubmed/21606539
Concomitant Highly Active
Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+
Cell Counts During and After Pegylated Interferon
Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients. Reiberger T,
Payer BA, Kosi L, et al. J Infect Dis. 2011 Jun;203(12):1802-1806.
http://www.ncbi.nlm.nih.gov/pubmed/21606538
Twice-weekly pegylated
interferon-α-2a and ribavirin results in superior
viral kinetics in HIV/hepatitis C virus co-infected patients compared to
standard therapy. Murphy AA, Herrmann E, Osinusi
AO, et al. AIDS. 2011 Jun 1;25(9):1179-1187.
http://www.ncbi.nlm.nih.gov/pubmed/21593619
Influence of
Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver
Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected
Patients Receiving Antiretroviral Therapy. Barreiro
P, Pineda JA, Rallón N, et al. J Infect Dis. 2011 Jun;203(11):1629-36.
http://www.ncbi.nlm.nih.gov/pubmed/21592993
Epidemiology,
Diagnostics, and Miscellaneous Works
Estimated
Risk of Human Immunodeficiency Virus and Hepatitis C Virus Infection among
Potential Organ Donors from 17 Organ Procurement Organizations in the United
States.
Ellingson K, Seem D, Nowicki M, et
al. Am J Transplant. 2011 Jun;11(6):1201-1208. doi:
10.1111/j.1600-6143.2011.03518.x.
http://www.ncbi.nlm.nih.gov/pubmed/21645253
Hepatitis
C Virus Adversely Affects Quality of Life. Cillo U, Amodio
P, Ronco C, et al. Blood Purif.
2011 Jun 10;32(2):144-149. [Epub
ahead of print]
Soni SS, Zanus
G, Minazzato L, Salari A, Neri D, Bombonato G, Schiff S, Bianco T.
http://www.ncbi.nlm.nih.gov/pubmed/21659741
Education
by a Nurse Increases Response of Patients With Chronic
Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin.
Larrey D, Salse
A, Ribard D, et al. Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21683161
Clarification
of interspousal hepatitis C virus infection in acute
hepatitis C patients by molecular evolutionary analyses: Consideration on
sexual and non-sexual transmission between spouses. Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21699638
Directly acting antivirals
against hepatitis C virus. Soriano V, Vispo
E, Poveda E, et al. J Antimicrob
Chemother. 2011 Jun 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21652618
Patient acceptance of universal screening for
hepatitis C virus infection. Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. BMC Infect Dis. 2011 Jun 6;11:160.
http://www.ncbi.nlm.nih.gov/pubmed/21645388
Role of Lifestyle Changes in the Management of
Chronic Liver Disease. Nobili V, Carter-Kent C, Feldstein AE. BMC
Med. 2011 Jun 6;9(1):70. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21645344
Liver
Cancer
Hepatitis
C virus infection induces the expression of amphiregulin,
a factor related to the activation of cellular survival pathways and required
for efficient viral assembly. Pei
R, Chen H, Lu L, et al. J Gen Virol. 2011 Jun 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21653755
Amino
acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis
following eradication of HCV RNA by antiviral therapy. Akuta N, Suzuki F, Hirakawa
M, et al. J Med Virol. 2011 Jun;83(6):1016-22.
doi: 10.1002/jmv.22094.
http://www.ncbi.nlm.nih.gov/pubmed/21503914
Hepatocellular nodules in liver
cirrhosis: MR evaluation. Lee
JM, Choi BI. Abdom Imaging. 2011 Jun;36(3):282-9.
http://www.ncbi.nlm.nih.gov/pubmed/21399975
Rising
incidence and demographics of hepatocellular
carcinoma in the USA: what does it mean? Shaw JJ, Shah SA. Expert Rev Gastroenterol
Hepatol. 2011 Jun;5(3):365-70.
http://www.ncbi.nlm.nih.gov/pubmed/21651354
Impact
of Pegylated Interferon Therapy on Outcomes of
Patients with Hepatitis C Virus-Related Hepatocellular
Carcinoma After Curative Hepatic Resection. Tanimoto Y, Tashiro
H, Aikata H, et al. Ann Surg
Oncol. 2011 Jun 28. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21710324
Serum
levels of β-catenin as a potential marker for
genotype 4/hepatitis C-associated hepatocellular carcinoma.
Zekri AR, Bahnassy
AA, Alam El-Din HM, et al. Oncol
Rep. 2011 Jun 21. doi:
10.3892/or.2011.1355. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21701780
Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.
Abu El Makarem MA, Abdel-Aleem A, Ali A,
Saber R, et al. Ann Hepatol. 2011 Jun 1;10(3):296-305.